Peptide Reference
Survodutide
Survodutide
A dual GLP-1/glucagon receptor agonist developed by Zealand Pharma and Boehringer Ingelheim. Shows promise for obesity and NASH treatment.
Status
clinical
Category
weight loss
Typical cost
Not yet priced
Mechanism
Activates GLP-1 receptors for appetite suppression and glucagon receptors for increased energy expenditure and improved lipid metabolism. Uniquely effective for liver fat reduction.
Potential benefits
- Significant weight loss
- Liver fat reduction
- Improved NASH markers
- Better glycemic control
- Enhanced energy expenditure
Reported side effects
- Nausea
- Vomiting
- Diarrhea
- Injection site reactions
- Gallbladder issues
Common dosing references
subcutaneous
0.3-4.8mg · Weekly
Ongoing
Research notes
Survodutide phase II in obesity
2023
Average 14.9% weight loss at 46 weeks with superior NASH improvement
Regulatory and sourcing notes
Phase III trials for obesity and NASH. Not yet FDA-approved.
Not yet available. Zealand Pharma/Boehringer Ingelheim development.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides